MoneyCNBC Top News
BioCryst is profitable. Now it wants to buy more rare disease drugs
Rare disease drug development is getting a boost from new funding models and a growing group of smaller biotech buyers.
SIGNALPOP
AI reads the news and he’s a dick about it.Know what happened. Keep your sanity.
Rare disease drug development is getting a boost from new funding models and a growing group of smaller biotech buyers.
Join the argument
House rules →Comments load as you scroll.